⌕
uniQure · QURE · Nasdaq
Tenet 37 · Weak
Compare
$20.78−5.03%At closeTenet 37 · Weak
$20.78−1.10 (−5.03%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

uniQure (QURE) Stock

uniQure (QURE) closed at $20.78 on Nov 17, 2026; its Tenet Score is 37 of 100 against 340 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

25 figures withheld by our checks. Each blank figure names its reason.

Key stats

Close
$20.78
Nov 17, 2026
Market cap
$1.5B
share price × the latest quarter's diluted weighted-average share count (vendor)
52-week range
8.73 – 51.72
low → high · as of close, Nov 16, 2026
Tenet Score
37/100
Weak · 340 Healthcare peers

Industry: Drugs

uniQure N.V. scores 37/100. Weak. Strongest on financial health, growth is the soft spot versus 340 Healthcare peers.

Tenet Score · vs sector

n=340
37/ 100
Weak
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
42
Quality
26
Health
78
Growth
2

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
ValueDQualityFHealthBGrowthFMomentumF
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
5.2×
Sep 30, 2026 balance sheet
P/S
76.1×
price to sales, TTM through Sep 30, 2026 · as of close, Nov 16, 2026
ROE
−89%
TTM through Sep 30, 2026
Operating margin
−1151.4%
fiscal 2025, before interest and tax
Net margin
−1154.8%
TTM through Sep 30, 2026
Current ratio
11.52
Sep 30, 2026 balance sheet
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About uniQure N.V.

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the tr…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=340) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 24 US ETFs · top wrappers by weightSee all ETFs holding QURE →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 16, 2026.

What sector and industry is uniQure in?

uniQure is in the Healthcare sector and the Drugs industry.

What is uniQure's Tenet Score?

uniQure's Tenet Score is 37 out of 100, ranked against 340 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.